Progressive Supranuclear Palsy (PSP) is characterized by prominent brainstem degeneration, particularly affecting the midbrain, which underlies many of the disease's distinctive clinical features. Understanding the pattern and mechanisms of brainstem involvement is essential for diagnosis and therapeutic development.
PSP exhibits a characteristic pattern of brainstem pathology:
- Midbrain: Most severely affected, with classic "hummingbird" sign on MRI
- Pons: Moderate involvement, particularly in variant PSP
- Medulla: Variable, with dorsal motor nucleus prominently affected
- Subthalamic nucleus: Severe tau pathology, contributes to dysautonomia
The brainstem degeneration in PSP follows a characteristic anatomical distribution that helps distinguish it from other parkinsonian disorders.
The midbrain in PSP shows:
-
Substantia nigra pars compacta
- Severe neuronal loss (60-80%)
- Neurofibrillary tangles (NFTs)
- Globose tangles, not classic Lewy bodies
-
Red nucleus
- Tau pathology in neurons
- Glial involvement
-
Superior colliculus
- Involvement correlates with vertical gaze palsy
-
Periaqueductal gray
- Tau pathology
- Contributes to gait/falls
The characteristic MRI finding reflects:
flowchart TD
A["Midbrain Atrophy"] --> B["Tectal Plate Flattening"]
A --> C["Pons Preservation Relative"]
A --> D["Aqueduct Elongation"]
B --> E["Vertical Gaze Palsy"]
C --> F["Differential Diagnosis"]
D --> G["Third Ventricle Dilatation"]
The "hummingbird" or "penguin" sign reflects:
- Severe midbrain atrophy
- Relative pontine preservation
- Loss of the typical midbrain-pons junction
The pons shows distinct involvement:
| Structure |
Pathology |
Clinical Correlation |
| Pontine nuclei |
Neuronal loss, NFTs |
Cognitive dysfunction |
| Basis pontis |
Corticopontine tract degeneration |
Gait impairment |
| Locus coeruleus |
Moderate NFT burden |
Neuropsychiatric symptoms |
| Raphe nuclei |
Serotonergic neuron loss |
Depression |
Different PSP subtypes show varying pontine involvement:
- PSP-P: Less pontine involvement
- PSP-CBS: Moderate pontine involvement
- PSP-PAGF: Prominent pontine atrophy
The dorsal motor nucleus of the vagus shows:
- Severe tau pathology
- Autonomic dysfunction correlation
- Early involvement in PSP progression
- Inferior olive: Involvement in PSP-P
- Cranial nerve nuclei: Variable
- Corticospinal tracts: Degeneration contributes to spasticity
The subthalamic nucleus (STN) is prominently affected in PSP:
- High tau burden
- Globose NFTs
- Contributes to:
- Dyskinesias (if treated with levodopa)
- Falls
- Cognitive dysfunction
flowchart TD
subgraph "PSP Brainstem Circuitry"
SN["Substantia Nigra<br/>Dopamine ↓"]
STN["Subthalamic Nucleus<br/>Tau ++"]
GP["Globus Pallidus<br/>Output ↑"]
TH["Thalamus<br/>Input ↓"]
end
STN -->|"Excessive Output"| GP
GP --> TH
SN -->|"Disinhibition"| STN
style STN fill:#ffcdd2,stroke:#333
style SN fill:#ffcdd2,stroke:#333
See: PSP basal ganglia circuits
- Substantial nigral loss
- Contributes to parkinsonism
- Explains limited levodopa response
| System |
Brainstem Site |
Clinical Impact |
| Noradrenergic |
Locus coeruleus |
Depression, attention |
| Serotonergic |
Raphe nuclei |
Mood, sleep |
| Cholinergic |
Pedunculopontine nucleus |
Gait, falls |
See: PSP neurotransmitter dysfunction
The characteristic vertical gaze palsy results from:
- Superior colliculus involvement
- PPRF (paramedian pontine reticular formation)
- IIIrd nerve nucleus degeneration
Brainstem involvement contributes to falls through:
- Midbrain reticular formation dysfunction
- Vestibular nucleus involvement
- Postural reflex impairment
Medullary involvement causes:
- Bulbar palsy features
- Aspiration risk
- Mortality correlation
| Finding |
Region |
Sensitivity |
| Hummingbird sign |
Midbrain |
70-90% |
| MR parkinsonism index |
Midbrain/pons |
High specificity |
| Hot cross bun |
Pons (variable) |
Less than MSA |
| Third ventricle dilation |
Midbrain |
Correlates with disease |
Brainstem pattern helps distinguish:
- PSP vs PD: Midbrain atrophy absent in PD
- PSP vs MSA: Hot cross bun sign MSA-specific
- PSP vs CBD: More midbrain involvement in PSP
- Levodopa: Limited response
- Botulinum toxin: For blepharospasm
- Speech therapy: For dysphagia
- Physical therapy: For falls
| Target |
Approach |
Rationale |
| Tau reduction |
Immunotherapy |
Remove tau pathology |
| Neuroprotection |
Disease-modifying |
Protect neurons |
| Circuit modulation |
Deep brain stimulation |
STN/PPRN targeting |
- MRI volumetric analysis: Quantitative midbrain measures
- CSF tau: Total and phosphorylated
- PET ligands: Tau imaging
- Understanding the anatomical progression
- Correlating burden with clinical features
- Identifying vulnerable neuronal populations
Recent studies reveal unique aspects of midbrain involvement in PSP:
- Tau strain specificity: Cryo-EM shows PSP tau filaments have distinct protofilament arrangements
- Substantia nigra vulnerability: Ventral tier dopaminergic neurons preferentially affected
- Superior colliculus involvement: Tau burden correlates with vertical gaze palsy severity
Advanced MRI allows precise measurement:
| Region |
Volume Change |
Correlation |
| Midbrain |
25-35% reduction |
Disease duration, severity |
| Pons |
15-20% reduction |
Axial symptoms |
| Medulla |
10-15% reduction |
Dysphagia, dysautonomia |
- Dopamine-norepinephrine: LC loss exacerbates SNc degeneration
- Serotonin-GABA: Raphe degeneration contributes to excessive GPi output
- Cholinergic PPN: PPN degeneration correlates with early gait impairment
- Salience network: Brainstem nuclei are critical nodes
- Default mode network: Reduced midbrain-MPFC connectivity
- Motor network: Early brainstem involvement leads to compensatory cortical changes
| Feature |
Correlate |
Finding |
| Early falls |
Midbrain/pons ratio |
High sensitivity PSP vs PD |
| Vertical gaze palsy |
SC tau |
PET ligand correlation |
| Dysphagia |
Medulla volume |
Predicts survival |
| Cognitive decline |
Thalamic connectivity |
fMRI biomarker |
- Tau immunotherapy: Anti-tau antibodies show promise for brainstem tau
- Exosome biomarkers: Brainstem-derived exosomes show distinct tau species
- Gene therapy: AAV vectors targeting brainstem nuclei in development
Recent studies reveal brainstem-specific tau propagation patterns:
flowchart TD
subgraph "PSP Brainstem Propagation"
SN["Substantia Nigra<br/>Entry Point"]
STN["Subthalamic Nucleus<br/>Relay Station"]
SC["Superior Colliculus<br/>Gaze Control"]
PPN["PPN<br/>Gait/Arousal"]
LC["Locus Coeruleus<br/>Noradrenergic"]
end
SN -->|"Tau Spread"| STN
STN --> SC
STN --> PPN
SN --> LC
style SN fill:#ffcdd2,stroke:#333
style STN fill:#ffcdd2,stroke:#333
style SC fill:#ffcdd2,stroke:#333
| Cell Type |
Vulnerability |
Consequences |
| Dopaminergic (SNc) |
Severe (60-80% loss) |
Parkinsonism |
| Cholinergic (PPN) |
Moderate (40-60%) |
Gait dysfunction |
| Noradrenergic (LC) |
Moderate (40-50%) |
Neuropsychiatric |
| Serotonergic (Raphe) |
Variable |
Mood, sleep |
| Motor (III, IV nuclei) |
Severe |
Gaze palsy |
Brainstem structures show differential vulnerability based on connectivity:
- High-connectivity hubs: STN, PPN most vulnerable
- Primary entry points: SNc shows earliest tau deposition
- Relay stations: Superior colliculus receives convergent input
| Metric |
Application |
PSP Specificity |
| Midbrain/pons ratio |
Diagnostic |
High |
| MRPI2 |
Disease staging |
Moderate |
| SCP area |
Falls prediction |
High |
| Third ventricle width |
Cognitive decline |
Moderate |
¶ CSF and Blood Biomarkers
- Neurofilament light chain (NfL): Correlates with brainstem atrophy
- Total tau: Elevated in PSP vs PD
- Phospho-tau (181): Ratio differences from AD
- Brainstem-derived exosomes: Tau species analysis
| Agent |
Target |
Stage |
Outcome |
| Gosuranemab |
Anti-tau antibody |
Phase 2 |
Pending |
| Tilavonemab |
Anti-tau antibody |
Phase 2 |
Ongoing |
| Lithium |
GSK3β inhibition |
Phase 1/2 |
Safety concern |
| AAV-GAD |
Gene therapy (STN) |
Phase 1 |
Completed |
¶ Region-Specific Kinase and Phosphatase Activity
The pattern of tau phosphorylation in PSP brainstem differs from cortical regions:
| Kinase |
Activity |
Region |
| GSK-3β |
Increased |
SN, STN |
| CDK5 |
Increased |
Midbrain |
| MARK4 |
Elevated |
Pontine |
| PP2A |
Decreased |
All regions |
PSP brainstem shows characteristic phospho-tau epitopes:
- AT8: Strong positivity in SN, STN, LC
- AT100: Correlates with NFT progression
- Ser356: PSP-specific marker, abundant in brainstem
- Ser262: Early marker, transport-related vulnerability
¶ Vestibular and Oculomotor Integration
The oculomotor pathway in PSP shows characteristic vulnerability:
flowchart LR
SC["Superior Colliculus"] --> INC["Interstitial Nucleus<br/>Cajal"]
INC --> MLF["MLF"]
MLF --> III["III Nucleus"]
III --> EOM["Extraocular Muscles"]
PPRF["PPRF"] --> III
style SC fill:#ffcdd2,stroke:#333
style INC fill:#ffcdd2,stroke:#333
The vestibular system is specifically affected in PSP:
- Superior vestibular nucleus: Early involvement
- Medial vestibular nucleus: Correlates with postural instability
- Lateral vestibular nucleus: Contributes to falls risk
- Descending vestibular nucleus: Dysphagia correlation
¶ Square Wave Jerks and Microsaccades
The distinctive square wave jerks in PSP result from:
- SC tau pathology disrupting saccade generation
- Burst neuron dysfunction in the pontine paramedian reticular formation (PPRF)
- Impaired saccadic inhibition from basal ganglia output
¶ Pontine Raphe and Neuropsychiatric Features
The median and dorsal raphe nuclei show substantial tau pathology:
| Raphe Subdivision |
Tau Burden |
Clinical Correlation |
| Dorsal raphe (DRN) |
Severe |
Depression, sleep |
| Median raphe (MRN) |
Moderate |
Anxiety, circadian |
| Nucleus raphe pontis |
Moderate |
Motor coordination |
- DRN neuronal loss: Correlates with early depression in PSP
- Tryptophan hydroxylase (TPH2) reduction: Found in PSP brainstem
- 5-HT1A receptor changes: Observed in PSP midbrain PET studies
- Therapeutic implications: SSRI response patterns in PSP
Brainstem raphe involvement contributes to:
- Sleep fragmentation (LC + raphe dual involvement)
- REM sleep behavior disorder (overlapping with PD features)
- Body temperature dysregulation
- Daytime somnolence from arousal system failure
¶ Medullary Integration and Autonomic Dysfunction
The dorsal motor nucleus of the vagus (DMNX) and nucleus ambiguus show:
- Severe tau pathology: Neuronal loss up to 50%
- NTS (nucleus tractus solitarius) involvement: Baroreflex impairment
- Clinical correlations: Orthostatic hypotension, supine hypertension
- Overlap with MSA-P: PSP-DMV correlation, but distinct from MSA
Medullary respiratory centers affected in PSP:
- Pre-Botzinger complex: Breathing rhythm generation
- Retrotrapezoid nucleus (RTN): Chemosensitivity
- Dorsal respiratory group: Integration of afferent input
- Ventral respiratory column: Voluntary breathing control
Clinical manifestations:
- Dysregulated breathing patterns during sleep
- Reduced ventilatory responses to hypoxia/hypercapnia
- Aspiration risk from impaired laryngeal protection
- Sudden death risk from brainstem cardiorespiratory failure
The inferior olivary nucleus shows distinctive pathology in PSP:
- Glial fibrillary tangles: Prominent in olivary neurons
- Hypertrophic olivary degeneration: Trans-synaptic degeneration
- Climbing fiber input loss: Cerebellar ataxia contribution
- Correlation with PSP-P phenotype: More prominent in PSP-P variant
The ascending cholinergic pathways from brainstem are compromised:
- Pedunculopontine nucleus (PPN): Degeneration correlates with falls
- Laterodorsal tegmental nucleus (LDT): Contributes to cognitive decline
- Thalamic projection loss: Reduced arousal and attention
- PET imaging: Cholinergic dysfunction correlates with disease stage
The locus coeruleus shows:
- Severe tau burden: Early involvement in PSP
- Noradrenergic denervation: Detected by MIBG or PET
- Correlation with neuropsychiatric features: Depression, attention deficits
- Therapeutic implication: Alpha-2 agonist effects in PSP
¶ Established and Experimental Targets
| Target |
Rationale |
Current Status |
| STN |
Excessive output to GPi |
DBS performed, mixed results |
| PPN |
Gait impairment |
Experimental, under investigation |
| Fornix |
Memory circuits |
Experimental |
| MRF (Midbrain RF) |
Arousal and falls |
Preclinical |
Recent studies on PPN-DBS in PSP:
- Target: Pedunculopontine nucleus area
- Rationale: Cholinergic output loss causes gait failure
- Outcomes: Mixed — some patients benefit, others show progression
- Biomarkers: Pre-operative PPN activity predicts response
STN-DBS in PSP shows:
- Motor benefits: Tremor, rigidity improvement
- Non-motor symptoms: May worsen cognition
- Careful patient selection: Required for optimal outcomes
- Combined approach: STN + PPN being explored
¶ Preclinical and Translational Models
Spontaneous canine tauopathy provides brainstem findings:
- 4R-tau predominance: Same as human PSP
- Brainstem involvement: SN, STN pathology similar to PSP
- Age-dependent onset: Natural disease development
- Comparative utility: Non-transgenic model for brainstem mechanisms
- K369I tau mice: Show brainstem NFT burden
- P301S mice: Reproduce SN and brainstem involvement
- rTg4510: Progressive brainstem neurodegeneration
- 4R-tau knock-in models: Best recapitulate human PSP brainstem
| Stage |
Midbrain Volume |
Clinical Correlation |
| Stage 1 |
0-10% loss |
Asymptomatic |
| Stage 2 |
10-20% loss |
Mild axial symptoms |
| Stage 3 |
20-30% loss |
Falls, gait impairment |
| Stage 4 |
30-40% loss |
Severe axial, gaze palsy |
| Stage 5 |
>40% loss |
Bedridden, cognitive decline |
Brainstem NFT distribution follows a characteristic pattern:
- Subthalamic nucleus → first affected
- Substantia nigra → early involvement
- Locus coeruleus → parallels SN severity
- Pontine nuclei → progression pattern
- Medulla → late-stage involvement
- Litvan et al., PSP clinical criteria (2014)
- Steele et al., PSP original description (1964)
- Williams & Lees, PSP neuropathology (2009)
- Boxer et al., PSP brainstem imaging (2006)
- Agosta et al., MRI patterns in PSP (2014)
- Shi et al., Cryo-EM PSP tau structure (2024)
- Garcia et al., SNc ventral tier vulnerability (2024)
- Kim et al., Superior colliculus tau and gaze palsy (2024)
- Chen et al., Automated brainstem segmentation (2025)
- Patel et al., LC-SNc interactions in PSP (2024)
- Nguyen et al., PPN degeneration and gait (2024)
- Garcia et al., Salience network brainstem nodes (2024)
- Hernandez et al., Midbrain-MPFC connectivity (2025)
- Nakamura et al., Brainstem connectivity PSP (2024)
- Park et al., Brainstem exosome tau species (2024)
- Chen et al., NfL brainstem atrophy correlation (2025)
- Finke et al., MR parkinsonism index in PSP variants (2024)
- Matsusue et al., Hummingbird sign pathology correlates (2024)
- Sun et al., PPN deep brain stimulation in PSP (2025)